Compare Moderna, Inc. (MRNA) vs Essential Utilities Inc. Common Stock (WTRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Essential Utilities Inc. Common Stock — how do they compare? Moderna, Inc. trades at $224.94 (market cap $86.33B), while Essential Utilities Inc. Common Stock trades at $39.82 (market cap $11.15B). The key difference: Moderna, Inc. is far larger — about 7.7× Essential Utilities Inc. Common Stock's market cap, and Essential Utilities Inc. Common Stock pays a 3.67% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Essential Utilities Inc. Common Stock for 0 Days on average.
| MRNA | WTRG | |
|---|---|---|
Market Cap | $86.33B | $11.15B |
Volume | 13,361,426 | 1,760,234 |
Sector | Health | Utilities |
52-Week High | $226.30 | $42.00 |
52-Week Low | $22.36 | $36.25 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $19.66B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
WTRG trades at $39.29, up 0.36% with neutral technical signals. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining strong profitability margins (21.6% net income margin). Analyst consensus is bullish with a $44.50 price target, supported by ongoing acquisitions and pending merger developments with American Water.
The stock presents a stable utility investment with moderate growth potential through strategic acquisitions, though near-term earnings volatility and integration risks from the pending merger warrant caution. Current valuation at 20.15 P/E appears reasonable given the company's consistent cash flow generation and defensive sector positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Essential Utilities Inc. Common Stock
Essential Utilities Inc. is a holding company for regulated water, wastewater, and natural gas utilities, operating under the Aqua and Peoples brands. It serves customers across Pennsylvania, Ohio, Texas, Illinois, North Carolina, New Jersey, Indiana, Virginia, and Kentucky.
Read more on WTRG →
